Therefore, the identification and development of new inhibitors targeting both ER and Hsp90 can represent a promising therapeutic strategy for the treatment of ER+ breast cancer, with the potential to significantly improve clinical outcomes for patients. Here, ESR1 is linked to breast cancer.